Jade Biosciences, Inc.
JBIOHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeJade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. Valued at $1.27B, JBIO is a small-cap name in its sector. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
Market Cap
$1.27B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-9.15
EPS (TTM)
$-2.68
EPS (Fwd)
$-2.28
ROE
—
ROA
—
Cash
$311.3M
Total Debt
$808,000
Free CF
—
52W Change
120.3%
Annual Financials
Cash vs Debt
Jade Biosciences, Inc. holds $311.3M in cash against $808K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining.
With cash comfortably exceeding debt, JBIO has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Jade Biosciences, Inc. and its sector.